Akari Therapeutics, Plc (AKTX) Stock Price

10.21 ▼ -0.04 (-0.39%)
Open: 10.24 Vol: 0 Day's range: 10.21 - 10.53 Sep 16, 10:45 EDT
IEX quote, 15 minutes delayed during trading hours. Login or Signup to see real-time data
Free Stock Screener
Loading chart ...
AKTX Technical Analysis
5 mins 30 mins Hourly Daily Weekly
SELL SELL SELL BUY SELL
  5 mins 30 mins Hourly Daily Weekly
MA5 10.44▼ 10.62▼ 10.62▼ 10.74▼ 10.31▼
MA10 10.76▼ 10.85▼ 10.84▼ 10.77▼ 9.36▲
MA20 10.90▼ 10.82▼ 10.82▼ 9.81▲ 10.63▼
MA50 10.86▼ 10.97▼ 10.71▼ 9.56▲ 12.45▼
MA100 10.78▼ 9.93▲ 9.27▲ 9.83▲ 30.62▼
MA200 9.46▲ 9.21▲ 10.05▲ 9.63▲ 97.56▼
  5 mins 30 mins Hourly Daily Weekly
MACD -0.098▼ -0.081▼ -0.102▼ 0.049▲ 0.471▲
RSI 37.482▼ 39.131▼ 41.457▼ 53.060▲ 48.132▼
STOCH 4.898▼ 31.323     38.869     48.531     41.071    
WILL %R -100.000▼ -100.000▼ -100.000▼ -57.059     -58.843    
CCI -137.163▼ -184.337▼ -141.489▼ -34.399     22.463    
Latest Filters Detected On AKTX
CDL $AKTX Matching Low Candlestick Pattern Detected Set Alert
CDL $AKTX Doji Star Candlestick Pattern Detected Set Alert
CDL $AKTX Doji Candlestick Pattern Detected Set Alert
Akari Therapeutics, Plc News
Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums
Tuesday, September 08, 2026 06:15 AM
Company invited to present alongside global pharmaceutical, biotechnology and industry leaders at five high-profile U.S. and China conferences in September CEO Abizer Gaslightwala to deliver keynote ...
Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy
Tuesday, August 18, 2026 01:53 AM
AKTX-101 demonstrated robust anti-tumor activity across multiple clinically relevant urothelial cancer preclinical models Data supports the potential of Akari’s novel PH1 RNA spliceosome-modulating ...
Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy
Tuesday, August 18, 2026 01:53 AM
AKTX-101 demonstrated robust anti-tumor activity across multiple clinically relevant urothelial cancer preclinical models Data supports the potential of Akari’s novel PH1 RNA spliceosome-modulating ...
AKTX historical stock data
date open high low close volume
16/09/26 10.24 10.53 10.21 10.21 10,162
15/09/26 11.05 11.05 10.00 10.25 27,586
14/09/26 11.43 11.61 10.68 11.04 39,960
11/09/26 10.51 11.50 10.51 11.30 133,264
10/09/26 10.63 11.065 10.07 10.88 165,986
09/09/26 10.89 12.15 10.0187 10.57 131,071
08/09/26 11.32 12.04 10.75 10.96 128,525
04/09/26 10.41 11.82 10.1703 11.47 108,162
03/09/26 10.00 11.40 9.65 10.84 61,947
02/09/26 10.09 10.40 9.60 10.15 46,491
Quote Details
52wk Low:3.015
52wk High:49.60
Vol:0
Avg Vol(3m):1.2M
1Y Chng:-72.66%
1M Chng:+36.13%
Add to Watch List
More Information
Index US Composite
Market Cap. 21.49M